Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.70 |
| ▸ | SRC | P12931 | 2/20 | 0.70 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.70 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.70 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.70 |
| ▸ | LDHA | P00338 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.70 |
| ▸ | FBP1 | P09467 | 1/20 | 0.70 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.70 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.70 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.70 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8328542 | 0.95 | ADORA1 (0.74) | P2RY1SMN1; SMN2P2RY2ADORA1SRC | |
| SCHEMBL8164443 | 0.91 | P2RY1 (0.68) | P2RY1SMN1; SMN2P2RY2ADORA1SRC | |
| SCHEMBL2534140 | 0.91 | EHMT1 (0.70) | P2RY1SMN1; SMN2P2RY2ADORA1SRC | |
| SCHEMBL384075 | 0.90 | ADORA1 (0.74) | P2RY1SMN1; SMN2P2RY2ADORA1SRC | |
| SCHEMBL15338536 | 0.90 | ADORA1 (0.74) | P2RY1SMN1; SMN2P2RY2ADORA1SRC | |
| SCHEMBL15926827 | 0.90 | ADORA1 (0.74) | P2RY1SMN1; SMN2P2RY2ADORA1SRC | |
| SCHEMBL41361 | 0.90 | ADORA1 (0.74) | P2RY1SMN1; SMN2P2RY2ADORA1SRC | |
| SCHEMBL15788449 | 0.90 | ADORA1 (0.74) | P2RY1SMN1; SMN2P2RY2ADORA1SRC | |
| SCHEMBL15338502 | 0.90 | ADORA1 (0.74) | P2RY1SMN1; SMN2P2RY2ADORA1SRC | |
| SCHEMBL29936504 | 0.90 | ADORA1 (0.74) | P2RY1SMN1; SMN2P2RY2ADORA1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229036-A9 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-07-11 | — | — | US | disclosed |
| WO-2024137993-A2 | ENGINEERED GUIDE RNAS AND POLYNUCLEOTIDES | SHAPE THERAPEUTICS INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240200061-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | ALNYLAM PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | disclosed |
| EP-4384617-A1 | FACTOR XII (F12) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4381071-A1 | IRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT) | Alnylam Pharmaceuticals, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4381067-A1 | TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4377458-A1 | 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4373933-A1 | BETA-CATENIN (CTNNB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240132893-A1 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4351541-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT'S DISEASE AND/OR RETINAL BINDING PROTEIN 4 (RBP4)-ASSOCIATED DISORDERS | Alnylam Pharmaceuticals, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2017019660-A1 | XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| EP-2970974-A2 | COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160129-A2 | COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-7371852-B2 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1585754-A2 | ALKYL-LINKED NUCLEOTIDE COMPOSITIONS | Serenex, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040215009-A1 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2004-10-28 | — | — | US | disclosed |
| US-6800751-B2 | ALKYLATION OF 2'-HYDROXY GROUP OF RIBONUCLEOSIDE PROTECTED WITH INVENTIVE SILYLATING AGENTS IN PRESENCE OF EXCESS OF MILD HINDERED BASE MAY BE CARRIED OUT WITHOUT PROTECTING EXOCYCLIC AMINE AND OXO FUNCTIONALITIES OF NUCLEOBASES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| WO-2004065566-A2 | ALKYL-LINKED NUCLEOTIDE COMPOSITIONS | SERENEX, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20030225262-A1 | Reagent and process for protecting active groups | IONIS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087053-A2 | REAGENT AND PROCESS FOR PROTECTING NUCLEOSIDE ACTIVE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225262-A1 | Reagent and process for protecting active groups | TRDMT1, SBDS, DIMT1 | P2RY1 4547/4885SMN1; SMN2 229/4885P2RY2 4172/4885 |
| US-20040215009-A1 | Alkyl-linked nucleotide compositions | NT5C3B, NUDT1, NT5C2 | P2RY1 446/4885SMN1; SMN2 2062/4885P2RY2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.